Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,587 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Juvenile Diabetes Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: cinnamon; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 13 Years to 18 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Type 1 Diabetes
Interventions: canagliflozin, basal interruption without canagliflozin; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes Mellitus, Type 1
Interventions: Parenteral Insulin, Close Observation, Oral Insulin, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 3 Years to 45 Years
Enrollment: 711 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 2003
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 10 more

Conditions: Diabetic Kidney Disease
Interventions: INV-202, Placebo; Drug
Lead sponsor: Inversago Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Garden Grove, California • Pomona, California • Salinas, California + 19 more

Conditions: Type 1 Diabetes
Interventions: Acipimox, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 25 Years to 59 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes
Interventions: Human Pancreatic Islet Transplantation; Biological
Lead sponsor: Midhat H. Abdulreda; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Advanced Hepatocellular Carcinoma
Interventions: Pembrolizumab/Quavonlimab, Lenvatinib, Pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Duarte, California • Baltimore, Maryland • New York, New York + 4 more

Conditions: Type 1 Diabetes
Interventions: Discovery Program; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 13 Years to 21 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 1 Diabetes Mellitus
Interventions: 'KnowIt', 'OnTrack'; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 19 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type 1
Interventions: Not listed
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 8 Years to 25 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Conditions: Diabetes Mellitus, Stress, Psychological, Stress, Physiological
Interventions: Stress Management and Resiliency Training (SMART) program; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Type 1 Diabetes
Interventions: Team Clinic Care, Standard Care; Other
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 10 Years to 17 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Basal insulin alone, Basal pramlintide and reduced basal insulin, CGM, Acetaminophen test, Insulin-induced hypoglycemia, Exercise-induced hypoglycemia; Other
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes
Interventions: CGM Intervention, SMBG Control Condition; Device · Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Middletown, Connecticut • Vero Beach, Florida

Conditions: Type 1 Diabetes Mellitus
Interventions: Multiple Model Predictive Controller; Device
Lead sponsor: Stanford University; Other
Eligibility: 21 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Stanford, California

Conditions: Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma
Interventions: INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody; Drug · Biological
Lead sponsor: Intensity Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 7
States / cities: Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Pops! One personalized mobile platform; Device
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: 10 Years to 25 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Type 1 Diabetes
Interventions: "MyPlan" - Individualized Planned Eating Pattern; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 17 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Cincinnati, Ohio

Conditions: Type1diabetes
Interventions: FREE; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions: XmAb®22841, Pembrolizumab (Keytruda®); Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Encinitas, California • La Jolla, California • Los Angeles, California + 15 more

Conditions: Diabetic Nephropathies
Interventions: Fenofibrate, Placebo; Drug · Other
Lead sponsor: Alessandro Doria; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Boston, Massachusetts • Burlington, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Diabetic Ketoacidosis, Uncontrolled Type 1 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: 7 Years to 18 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Minneapolis and Saint Paul, Minnesota

Conditions: Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions: Ruboxistaurin mesylate; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 19
States / cities: Mesa, Arizona • Irvine, California • Los Angeles, California + 16 more

Conditions: Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions: G-Pen, Lilly Glucagon; Drug
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 4
States / cities: Chula Vista, California • Walnut Creek, California • Atlanta, Georgia + 1 more

Search by objective public record fields.

The Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes

Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes

Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Discovery Diabetes

Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes

Patient and Parent Preferences for an On-Body Automated Insulin Delivery System

A Mind-Body Intervention for Diabetes Management: A Pilot Study

Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes

Glucagon Counterregulation in Type 1 Diabetes

Pilot RCT: FQHC Intervention for Uptake of CGM in Low-Income Adults With T1D

A Study to Evaluate a Multiple Model Probabilistic Predictive Controller (MMPPC) for Closed Loop Insulin Delivery

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Pediatrics Owning Performance Study

"MyPlan" - Individualized Planned Eating Patterns for Adolescents With Type 1 Diabetes

A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

DKA Optic Ultrasound

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes